Keith A. Markey, PhD,

Keith A. Markey, PhD,, Scientific Director - Biotechnology

Keith Markey is an equities analyst with more than 25 years of experience. In addition to conducting research, he provides advisory services on partnering/licensing, mergers/acquisitions, and financing for companies in the biotechnology, pharmaceutical, and medical device sectors. Previously, Keith held various managerial positions in the Value Line Research Department, supporting the Value Line Investment Survey with original research and by selecting stocks for coverage. He began his career as a biochemist, working in the fields of endocrinology and neuroscience. His research, which resulted in more than 30 publications, contributed to our understanding of regulatory biochemistry and stem cell plasticity. Keith has lectured on scientific and financial subjects and is a member of the Licensing Executive Society and the National Association of Science Writers. He earned a Ph.D. in Neurochemistry from the University of Connecticut and an M.B.A. in Finance from the Leonard N. Stern School of Business at New York University.  |  direct 212.514.7914 |  cell 908.334.3008

Morris Ajzenman, CFA

Morris Ajzenman, CFA, Senior Research Analyst - Value Stocks

Morris Ajzenman, CFA, has 30 years of experience specializing in smallcapitalization companies. His career includes co-managing $4 billion in assets for Lazard Asset Management, $2 billion at Mitchell Hutchins (division of Paine Webber), as well as managing long/short portfolios at 2 other firms. Morris’ approach is designed to identify companies that are expected to remain profitable, particularly during recessions. Morris focuses on companies that: generate free cash flow; sell at low multiples of C/F; have little debt; have appropriate levels of cash; have conservative accounting practices (e.g. where companies do not delegate liabilities to only footnotes); have a "moat around its castle"; have a catalyst or strategic action by management to unlock value; and, stocks selling at historic low valuations.  |  direct 646.442.1442 |  cell 516.503.6611

Jay Vleeschhouwer

Jay Vleeschhouwer, Managing Director - Software Research

Mr. Vleeschhouwer has over thirty years of research analyst experience. He has covered the technology sector since 1983, including more than 20 years of consistent coverage of the design software market. In addition to software research, he has over the years covered the imaging technology and computer hardware sectors. He was a senior analyst and managing director with Merrill Lynch, prior to which he was with such firms as Josephthal Lyon & Ross, Bear Stearns, and Cantor Fitzgerald. His work has been recognized on numerous occasions in the annual Institutional Investor and Greenwich Associates rankings of analysts, and he has been invited to present at various industry and corporate conferences and events on his perspectives of the software and imaging technology industries. Mr. Vleeschhouwer received his B.A degree, in Economics and Political Science, from the University of California, Los Angeles, and his M.B.A. degree from the University of California, Berkeley.  |  direct 646.442.4251 |  cell 917.543.2576

Kevin Simpson

Kevin Simpson, Energy Strategist

Mr. Simpson has over 35 years of experience as a leading oil service analyst and strategist, including 10 years each at Merrill Lynch and Drexel Burnham Lambert. Kevin was ranked as an Institutional Investor All Star analyst 17 times and ranked for oil service earnings accuracy by the WSJ for 6 consecutive years. He was lead analyst on 28 equity offerings including the IPOs of National Oilwell Varco, FMC Technologies and Oil States Intl. Most recently, Kevin was Energy Strategist at Miller Tabak. He has a BS in Economics from Wharton and is a Chartered Financial Analyst (CFA).  |  direct 646.350.4168 |  office 212.509.9500 |  cell 917.817.6916 |  trading 646.442.4255

© Copyright 2017 , Griffin Securities, Inc. All rights reserved.